Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 9% Improvement Relative Risk Case (b) 12% c19early.org/d Li et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 18,148 patients in the USA No significant difference in cases Li et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.11634 Favors vitamin D Favors control
Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults
Li et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.11634
Li et al., Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults, JAMA Network Open, doi:10.1001/jamanetworkopen.2021.11634
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Cohort study of 18,148 patients in the USA showing low vitamin D associated with COVID-19 PCR+ status before adjustments but not after.
Authors state that "low vitamin D levels were not independently associated with the
risk of seropositivity", however there is significant correlation between some adjustment variables and vitamin D levels in the logistic regression that prevent drawing this conclusion [statisticsbyjim.com]. Details of the logistic regression in the matched sample set are not provided.
Authors analyze only 20ng/mL and 30ng/mL cutoff points, other studies use 10ng/mL (or 12), where more significant differences are typically seen.
risk of case, 8.6% lower, RR 0.91, p = 0.24, high D levels 610 of 13,650 (4.5%), low D levels 290 of 4,498 (6.4%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, Figure 2.
risk of case, 12.4% lower, RR 0.88, p = 0.07, high D levels 289 of 7,272 (4.0%), low D levels 611 of 10,876 (5.6%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >30ng/mL, Figure 2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 19 May 2021, retrospective, USA, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Original Investigation | Infectious Diseases Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults Yonghong Li, PhD; Carmen H. Tong, MS; Lance A. Bare, PhD; James J. Devlin, PhD Abstract Key Points IMPORTANCE Low vitamin D levels have been reported to be associated with increased risk of SARS-CoV-2 infection. Independent, well-powered studies could further our understanding of this association. Question Are low levels of vitamin D independently associated with the risk of SARS-CoV-2 seropositivity? Findings In this cohort study of 18 148 OBJECTIVE To examine whether low levels of vitamin D are associated with SARS-CoV-2 individuals whose vitamin D levels were seropositivity, an indicator of previous infection. measured before the COVID-19 pandemic, low levels of vitamin D were DESIGN, SETTING, AND PARTICIPANTS This is a cohort study of employees and spouses who associated with SARS-CoV-2 elected to be tested for SARS-CoV-2 IgG as part of an annual employer-sponsored health screening seropositivity in unadjusted univariable program conducted in August to November 2020. This program includes commonly assessed analysis. However, after adjusting for demographic, biometric, and laboratory variables, including total vitamin D measurement. Baseline potentially confounding factors, (prepandemic) levels of vitamin D and potential confounders were obtained from screening results including age, sex, race/ethnicity, from the previous year (September 2019 to January 2020). Data analysis was performed from education, body mass index, blood December 2020 to March 2021. pressure, smoking status, and geographical location, vitamin D level EXPOSURES Low total serum 25-hydroxyvitamin D, defined as either less than 20 ng/mL or less was not associated with SARS-CoV-2 than 30 ng/mL. seropositivity. Meaning Although SARS-CoV-2– MAIN OUTCOMES AND MEASURES The main outcome was SARS-CoV-2 seropositivity, as determined with US Food and Drug Administration emergency use–authorized assays. The seropositive individuals did have lower vitamin D levels than seronegative association of SARS-CoV-2 seropositivity with vitamin D levels was assessed by multivariable logistic regression analyses and propensity score analyses. individuals, low vitamin D levels were not independently associated with the risk of seropositivity. RESULTS The 18 148 individuals included in this study had test results for SARS-CoV-2 IgG in 2020 and vitamin D levels from the prepandemic and pandemic periods. Their median (interquartile range) age was 47 (37-56) years, 12 170 (67.1%) were women, 900 (5.0%) were seropositive, 4498 (24.8%) had a vitamin D level less than 20 ng/mL, and 10 876 (59.9%) had a vitamin D level less than 30 ng/mL before the pandemic. In multivariable models adjusting for age, sex, race/ethnicity, education, + Invited Commentary + Supplemental content Author affiliations and article information are listed at the end of this article. body mass index, blood pressure, smoking status, and geographical location, SARS-CoV-2 seropositivity was not associated with having a vitamin D level less than 20 ng/mL before (odds ratio [OR], 1.04; 95% CI, 0.88-1.22) or during (OR, 0.93; 95% CI, 0.79-1.09) the pandemic; it was also not associated with having a vitamin D level less than 30 ng/mL before (OR, 1.09; 95% CI, 0.93-1.27) or during (OR, 1.05; 95% CI, 0.91-1.23) the pandemic. Similar results were..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit